Cidara Therapeutics, Inc. (NASDAQ:CDTX) Insider Taylor Sandison Sells 924 Shares of Stock

Cidara Therapeutics, Inc. (NASDAQ:CDTX) insider Taylor Sandison sold 924 shares of the stock in a transaction that occurred on Wednesday, September 11th. The stock was sold at an average price of $11.64, for a total value of $10,755.36. Following the sale, the insider now owns 23,067 shares in the company, valued at $268,499.88. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Cidara Therapeutics Trading Up 5.2 %

CDTX stock opened at $11.94 on Friday. Cidara Therapeutics, Inc. has a 1 year low of $10.00 and a 1 year high of $24.40. The company has a fifty day simple moving average of $12.17 and a 200 day simple moving average of $13.24. The firm has a market cap of $84.06 million, a PE ratio of -1.55 and a beta of 1.04.

Cidara Therapeutics (NASDAQ:CDTX) last posted its earnings results on Tuesday, August 13th. The biotechnology company reported ($2.05) earnings per share for the quarter, topping the consensus estimate of ($3.94) by $1.89. Cidara Therapeutics had a negative return on equity of 109.89% and a negative net margin of 289.05%. The firm had revenue of $0.30 million during the quarter. As a group, analysts forecast that Cidara Therapeutics, Inc. will post -12.06 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have commented on CDTX. Needham & Company LLC restated a “buy” rating and issued a $25.00 price target on shares of Cidara Therapeutics in a research note on Wednesday, August 14th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Cidara Therapeutics in a research note on Wednesday, August 14th. HC Wainwright raised Cidara Therapeutics from a “neutral” rating to a “buy” rating and set a $24.00 target price for the company in a report on Wednesday, August 14th. Finally, StockNews.com raised shares of Cidara Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday. One research analyst has rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Cidara Therapeutics has an average rating of “Buy” and an average price target of $29.67.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Cidara Therapeutics stock. Tocqueville Asset Management L.P. raised its position in shares of Cidara Therapeutics, Inc. (NASDAQ:CDTX) by 71.6% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 163,000 shares of the biotechnology company’s stock after acquiring an additional 68,000 shares during the period. Tocqueville Asset Management L.P. owned approximately 3.57% of Cidara Therapeutics worth $150,000 as of its most recent SEC filing. 35.82% of the stock is owned by institutional investors.

About Cidara Therapeutics

Cidara Therapeutics, Inc, a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates.